Skip to main content

Market Overview

Benzinga's Top Initiations

Benzinga's Top Initiations

Analysts at Standpoint Research initiated coverage on Coherus Biosciences Inc (NASDAQ: CHRS) with a Speculative Buy rating. The price target for Coherus Biosciences is set to $40. Coherus Biosciences shares closed at $28.10 on Wednesday.

Latest Ratings for CHRS

Feb 2021HC Wainwright & Co.MaintainsBuy
Nov 2020MizuhoMaintainsBuy
Nov 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for CHRS
View the Latest Analyst Ratings


Related Articles (CHRS)

View Comments and Join the Discussion!

Posted-In: Top InitiationsInitiation Analyst Ratings

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at